Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Launched by WANBANGDE PHARMACEUTICAL GROUP CO., LTD · Jul 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called huperzine A, which comes in a special controlled-release tablet form, to see if it can help people with mild to moderate Alzheimer’s dementia. The goal is to find out how well the medicine works to improve thinking and daily functioning, and to check if it’s safe to use over a longer period. The study will start by testing different doses to find the best one, then look more closely at how effective that dose is. After that, everyone in the study will have the chance to take the medication for up to a year to see how it works over time.

People who may be eligible to join are adults aged 50 to 85 years who have been diagnosed with probable Alzheimer’s dementia and have mild to moderate memory and thinking problems. Participants need to have had memory issues for at least a year, be able to complete simple memory tests, and have a stable caregiver who can help with the study visits and provide information about their condition. During the study, participants will be randomly assigned to receive either the medication or a placebo (a look-alike pill with no active medicine), and neither they nor the researchers will know who is getting which at first. The study also involves brain scans and other assessments to monitor progress and safety. This trial is not yet recruiting, but it offers a careful and closely watched opportunity for people with Alzheimer’s to try a new treatment while helping researchers learn more about managing this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The subject voluntarily agrees to participate in the study and signs the informed consent form jointly with a legally authorized representative (LAR). If the subject is unable to sign due to cognitive impairment or other reasons, the signature field for the subject may be left blank, with the reason specified and signed by the LAR. In such cases, the LAR must sign the informed consent form on behalf of the subject.
• • 2. Aged ≥50 and ≤85 years, male or female.
• • 3. Meets the diagnostic criteria for probable Alzheimer's disease (AD) dementia according to the 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) guidelines.
• • 4. Has experienced memory impairment for at least 12 months, with a chronic and progressively worsening course.
• • 5. Has received ≥5 years of formal education and is able to complete the protocol-specified cognitive assessments.
• • 6. Diagnosed with Stage 4 or 5 (mild to moderate dementia) according to the Revised Clinical Staging of Alzheimer's Disease (2024) (i.e., Clinical Dementia Rating \[CDR\] global score of 1 or 2).
• • 7. Total score on the Mini-Mental State Examination (MMSE) is between 11 and 26 inclusive.
• • 8. Has undergone a cranial MRI scan showing a Medial Temporal Atrophy (MTA) visual rating scale grade ≥1. If the subject has completed an eligible MRI at this or another tertiary hospital within 6 months prior to screening, and it meets the protocol requirements, re-scanning is not required.
• • 9. Capable of undergoing positron emission tomography (PET) imaging.
• • 10. Hachinski Ischemic Score (HIS) ≤ 4.
• • 11. Hamilton Depression Rating Scale (HAMD-17) score of ≤10.
• • 12. No obvious focal neurological signs on physical examination, except those attributable to peripheral injury.
• • 13. Has a stable and reliable caregiver, or is in frequent contact with a caregiver (at least 4 days per week and ≥2 hours per day). The caregiver must accompany the subject to study visits, provide reliable information for scale assessments based on sufficient interaction and communication with the subject, and should remain the same throughout the study whenever possible.
• Exclusion Criteria:
• • 1. Subjects who are allergic to the active ingredient or excipients of huperzine A controlled-release tablets or donepezil, or those with lactose intolerance.
• 2. Cognitive impairment or dementia not caused by Alzheimer's disease (AD), including:
• • (1) Other neurodegenerative diseases (e.g., dementia with Lewy bodies, frontotemporal degeneration, Huntington's disease, Parkinson's disease); (2) Non-degenerative neurological conditions causing cognitive impairment or dementia (e.g., vascular cognitive impairment or dementia, hydrocephalus, encephalitis, hypoxic brain injury, traumatic brain injury); (3) Non-neurological systemic diseases causing cognitive impairment or dementia (e.g., endocrine disorders such as hypothyroidism, hepatic insufficiency, hepatic encephalopathy, dialysis encephalopathy, neurosyphilis, HIV); (4) Cognitive impairment or dementia caused by vitamin deficiencies (e.g., folate or vitamin B12 deficiency).
• • 3.Subjects diagnosed, per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with psychiatric disorders within the past 12 months that are unstable or may interfere with study assessments, including but not limited to schizophrenia or other psychotic disorders, bipolar disorder, major depressive disorder, delirium, or substance (including alcohol) use disorders with dependence.
• 4.Subjects with significant focal brain lesions on MRI, including but not limited to any of the following (if a qualifying head MRI was performed within 6 months prior to screening and meets protocol requirements, repeat imaging is not required):
• • 1. Presence of lesions indicating large-area cerebral infarction;
• • 2. Infarcts in critical brain regions (e.g., thalamus, hippocampus, entorhinal cortex, parahippocampal gyrus, angular gyrus, cortical or subcortical gray matter nuclei);
• • 3. More than two infarcts with a diameter \>2 cm, and deemed by the investigator to impact cognitive assessments;
• • 4. Multiple lacunar infarcts, deemed by the investigator to impact cognitive assessments;
• • 5. Severe white matter lesions;
• • 6. Intracerebral hemorrhage deemed likely to affect cognitive assessments by the investigator;
• • 7. Hydrocephalus.
• • 5.Subjects with uncontrolled seizures (and/or epilepsy syndromes), or those with cognitive impairment caused or potentially caused by recurrent seizures or antiepileptic drug use.
• • 6.Subjects who experienced acute cardiovascular or cerebrovascular events within 3 months prior to screening (e.g., unstable angina, second- or third-degree atrioventricular block or other serious arrhythmias, myocardial infarction, decompensated congestive heart failure of NYHA class III or IV, transient ischemic attack, or ischemic stroke).
• • 7.Subjects with uncontrolled hypertension or hypotension at screening (defined as systolic blood pressure ≥160 mmHg or \<90 mmHg, or diastolic blood pressure ≥100 mmHg or \<60 mmHg after pharmacologic or non-pharmacologic treatment); subjects with slight deviations beyond this range but deemed clinically insignificant by the investigator may be included.
• • 8.Subjects with serious active gastrointestinal disorders (e.g., severe gastroesophageal reflux, gastrointestinal bleeding, or peptic ulcers) within 3 months prior to screening, or who have undergone any surgical procedures that may affect drug absorption (e.g., total gastrectomy, total small bowel resection).
• • 9.Subjects with other uncontrolled clinical conditions (e.g., malignancies, severe infectious diseases, respiratory diseases).
• • 10.Subjects with sinus bradycardia at screening (resting heart rate \<60 bpm) that is deemed clinically significant by the investigator.
• • 11.Subjects with corrected QT interval using Fridericia's formula (QTcF) \>450 ms in males or \>470 ms in females at screening or baseline.
• • 12.Subjects with renal dysfunction (serum creatinine \[Scr\] \>1.5× the upper limit of normal \[ULN\] per the study center laboratory) or hepatic dysfunction (ALT or AST \>2× ULN).
• • 13.Subjects with thyroid function abnormalities at screening that are deemed clinically significant and unsuitable for study participation by the investigator.
• • 14.Subjects who test positive for syphilis antibodies or HIV antibodies. 15.Subjects who received donanemab within 2 months prior to screening; lecanemab within 5 weeks prior to screening; or any other medication for the treatment of AD or cognitive enhancement within 4 weeks prior to screening, including but not limited to cholinesterase inhibitors, NMDA receptor antagonists, and other nootropic agents.
• • 16.Subjects who participated in any drug clinical trial (excluding vitamins and minerals) within 1 month prior to screening or 7 half-lives of the study drug (whichever is longer), or who are currently participating in another clinical trial.
• • 17.Subjects who are unable to complete the required scale assessments due to uncorrectable vision or hearing impairments.
• • 18.Subjects who are unable to complete study-required assessments due to personal limitations, such as contraindications to MRI scanning.
• • 19.Subjects of childbearing potential (male or female) who are unwilling to use effective contraception from the start of the study until 6 months after the end of the study, and/or female subjects of childbearing potential who are unwilling or unable to undergo pregnancy testing.
• • 20.Pregnant or breastfeeding women. 21.Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in the study.